You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 160 No. 16, September 11, 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (7)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Hyperforin in Extracts of St John's Wort (Hypericum perforatum) for Depression

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with interest the article of Gaster and Holroyd1 on St John's wort for depression. However, the authors do not mention the substance hyperforin as a component of Hypericum extracts. Hyperforin was first mentioned,2-3 and again recently discussed,4-5 as an antibiotic.

In the context of depression, hyperforin is a potent uptake inhibitor of serotonin, dopamine, noradrenaline, and {gamma}-aminobutyric acid, with IC50 values (concentration resulting in 50% inhibition) of about 0.05 to 0.1 µg/mL in synaptosomal preparations.6 The mechanism may be unique by elevating intracellular sodium ion concentration,7 but further effects of hyperforin on ionic conductances have been described,8 and the clinical relevance is unclear so far.

Hyperforin is thought to be the neurotransmitter reuptake-inhibiting constituent of Hypericum extract.9 Hyperforin also seems to be the active principle of Hypericum extracts in animal models of depression.10 Finally, in a clinical study, hyperforin has been shown to be the active principle in . . . [Full Text of this Article]



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
Sparreboom et al.
JCO 2004;22:2489-2503.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.